 |
12 Diseases |  |
17 Trials |
|
17 Trials |  |
2487 News |  |
| «12...13141516171819202122232425» |
- Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Treatment response to erenumab in refractory migraine patients (Room: Screen B4) - Apr 9, 2020 - Abstract #EAN2020EAN_1251;
6-month treatment of Erenumab is effective in reducing migraine severity and patients’ disability in refractory migraine in a daily-life setting.
- topiramate / Generic mfg., Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Design and population characteristics of the first head-to-head comparison of erenumab and topiramate with regards to tolerability and efficacy in episodic and chronic migraine patients (Room: Room Vienna) - Apr 9, 2020 - Abstract #EAN2020EAN_1063;
6-month treatment of Erenumab is effective in reducing migraine severity and patients’ disability in refractory migraine in a daily-life setting. This analysis will provide insights into the patient population enrolled in the first head-to-head trial comparing the tolerability and efficacy of erenumab and topiramate.
- Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Cardiovascular safety of erenumab in patients with migraine with or without a history of aura (Room Vienna) - Apr 9, 2020 - Abstract #EAN2020EAN_1062;
This analysis will provide insights into the patient population enrolled in the first head-to-head trial comparing the tolerability and efficacy of erenumab and topiramate. The vascular safety profile of long-term erenumab treatment was similar in patients both with and without a history of aura and was comparable to that of placebo over 12 weeks, with no increased emergence of events over time.
- Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] First data collection on the use of prophylactic migraine treatments including the monoclonal antibody Erenumab focused on the patient’s personal experience (Room Lisbon) - Apr 9, 2020 - Abstract #EAN2020EAN_894;
The vascular safety profile of long-term erenumab treatment was similar in patients both with and without a history of aura and was comparable to that of placebo over 12 weeks, with no increased emergence of events over time. PERISCOPE provides us the 1st real world data of German patients treated with erenumab and shows that patients’ benefit from erenumab treatment with regard to improvement of quality of life and reduction of migraine specific symptoms.
- Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Real-world Trends in Characteristics of Migraine Patients Newly Initiated on Erenumab in the United States (Room Lisbon) - Apr 9, 2020 - Abstract #EAN2020EAN_891;
Patients initiating erenumab had a higher comorbidity burden (anxiety, depression, and hypertension) in real-world compared with the general migraine population. Over time, a broader population of migraine patients received erenumab, and more general practitioners prescribed erenumab.
- Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Characterisation of prescription patterns in episodic and chronic migraine patients starting treatment in a real life setting with erenumab in Germany (SPECTRE) – A real world evidence study (Room Vienna) - Apr 9, 2020 - Abstract #EAN2020EAN_880;
The SPECTRE study will give us valuable insights into the clinical routine of erenumab prescriptions in Germany. Characterization of the prescription pattern and analysis of the respective therapy response will possibly allow to develop individual treatment strategies for each patient.
- Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Neurophysiological, biomolecular and psychological predictors of response to Erenumab in chronic migraine (ePoster) - Apr 9, 2020 - Abstract #EAN2020EAN_537;
Characterization of the prescription pattern and analysis of the respective therapy response will possibly allow to develop individual treatment strategies for each patient. Neurophysiological recorded spinal sensi- tization may represent a predictor of response of Erenumab in the management of CM associated or not with MO.
- Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Slovenian experience with erenumab (ePoster) - Apr 9, 2020 - Abstract #EAN2020EAN_535;
In our experince erenumab is effective and safe for reducing migraine burden in patients with 2 or more failed prophylactic treatments. This is in line with previously published data from clinical randomized studies.
- |||| Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion date, Trial primary completion date: OASIS (EM): Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine (clinicaltrials.gov) - Apr 8, 2020
P3, N=456, Recruiting, Sponsor: Amgen
This is in line with previously published data from clinical randomized studies. Trial completion date: May 2025 --> Aug 2025 | Trial primary completion date: May 2024 --> Aug 2024
- |||| Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion date, Trial primary completion date: OASIS (CM): Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine (clinicaltrials.gov) - Apr 8, 2020
P3, N=286, Recruiting, Sponsor: Amgen
Trial completion date: May 2025 --> Aug 2025 | Trial primary completion date: May 2024 --> Aug 2024 Trial completion date: May 2025 --> Aug 2025 | Trial primary completion date: May 2024 --> Aug 2024
- ||||||| Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion: EMPOwER: Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients (clinicaltrials.gov) - Apr 8, 2020
P3, N=900, Completed, Sponsor: Novartis Pharmaceuticals
Trial completion date: May 2025 --> Aug 2025 | Trial primary completion date: May 2024 --> Aug 2024 Active, not recruiting --> Completed
- || Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal: Erenumab (Aimovig) for Migraine Prophylaxis in Adults. (Pubmed Central) - Apr 4, 2020
Active, not recruiting --> Completed No abstract available
- Tirosint (levothyroxine) / IBSA Institute Biochemical SA, sumatriptan succinate / Generic mfg., Aimovig (erenumab) / Amgen, Novartis
Resolution of Hashimoto Thyroiditis: A Case of Hashimoto Thyroiditis Evolving Into Subacute Thyroiditis and Euthyroidism (ENDOExpo) - Apr 1, 2020 - Abstract #ENDO2020ENDO_4152;
Early in the disease course, hyperthyroidism may result from destruction of the thyroid gland cells. HT is known to be a life-long disorder with essentially a non-functional thyroid.
- || sumatriptan succinate / Generic mfg., Aimovig (erenumab) / Amgen, Novartis
Clinical, P1 data, Journal: Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers. (Pubmed Central) - Mar 26, 2020
P1
Conclusion Co-administration of erenumab and sumatriptan had no additional effect on resting blood pressure or on pharmacokinetics of sumatriptan. ClinicalTrials.gov, NCT02741310.
- | TEV-48125 / Teva, Ajovy (fremanezumab) / Otsuka, Teva
Preclinical, Journal: Fremanezumab inhibits vasodilatory effects of CGRP and capsaicin in rat cerebral artery - Potential role in conditions of severe vasoconstriction. (Pubmed Central) - Mar 26, 2020
Capsaicin is used as a pharmacological tool to induce secretion of endogenous perivascular CGRP and our studies confirm that the antibody reach the perivascular sensory synaptic cleft and blocks the vasodilatory response of released CGRP in the present in vitro model. Thus, CGRP neutralization might have the mechanistic potential to block vasoprotective responses to severe vasoconstriction provided they reach the site of action and Fremanezumab is an important tool for future investigations of the impact of CGRP physiology.
- | #FierceMadness, ready to roll: Play-in winners Dovato, Nubeqa, Doptelet and Aimovig move into Round 2 https://t.co/NnSSCp5z6F (Twitter) - Mar 23, 2020
- | Aimovig (erenumab) / Amgen, Novartis
Journal: Erenumab: A novel calcitonin gene-related peptide receptor antagonist developed specifically for migraine prevention. (Pubmed Central) - Mar 17, 2020
However, long-term outcomes and adverse effects still are under research. The following article elaborates on the current literature and evidence on this novel drug.
- | Aimovig (erenumab) / Amgen, Novartis
I hope Aimovig now gets approved on the nhs. (Twitter) - Mar 13, 2020
- | Aimovig (erenumab) / Amgen, Novartis
Hopefully they decide to actually prescribe it unlike Erenumab. (Twitter) - Mar 12, 2020
- | Aimovig (erenumab) / Amgen, Novartis
will this impact the Aimovig decision? (Twitter) - Mar 12, 2020
- | Aimovig (erenumab-aooe) / Amgen, Novartis
New P2 trial: Erenumab For Treatment of Hemicrania Continua (clinicaltrials.gov) - Mar 11, 2020
P2, N=20, Not yet recruiting, Sponsor: Mayo Clinic
- |||| Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment open: APOLLON: Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study (clinicaltrials.gov) - Mar 10, 2020
P4, N=560, Recruiting, Sponsor: Novartis Pharmaceuticals
The following article elaborates on the current literature and evidence on this novel drug. Not yet recruiting --> Recruiting
- Botox (onabotulinumtoxin A) / GSK, Allergan, Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] COST-EFFECTIVENESS ANALYSIS OF ERENUMAB FOR THE PROPHYLACTIC TREATMENT OF EPISODIC AND CHRONIC MIGRAINE ON PRIVATE HEALTH INSTITUTIONS IN MEXICO. () - Mar 8, 2020 - Abstract #ISPOR2020ISPOR_371;
Not yet recruiting --> Recruiting The use of erenumab is a cost-effective approach for preventing monthly migraine days among patients with chronic migraine versus onabotulinumtoxin A and no preventive treatment among patients with episodic migraine in the Mexican private health care context.
- || Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion date, Trial primary completion date: Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine (clinicaltrials.gov) - Mar 5, 2020
P4, N=340, Recruiting, Sponsor: Amgen
The use of erenumab is a cost-effective approach for preventing monthly migraine days among patients with chronic migraine versus onabotulinumtoxin A and no preventive treatment among patients with episodic migraine in the Mexican private health care context. Trial completion date: Apr 2021 --> Mar 2022 | Trial primary completion date: Apr 2021 --> Mar 2022
- || Aimovig (erenumab) / Amgen, Novartis
Review, Journal: Dawn of a New RAMPage. (Pubmed Central) - Mar 3, 2020
The consequences of these interactions on GPCR function and physiology lays the foundation for new molecular therapeutic targets, as evidenced by the recent success of erenumab. Here, we highlight recent papers that uncovered novel RAMP-GPCR interactions, human RAMP-GPCR disease-causing mutations, and RAMP-related human pathologies, paving the way for a new era of RAMP-targeted drug development.
- |||| Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo
New P4 trial: A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP Antagonist (clinicaltrials.gov) - Mar 3, 2020
P4, N=60, Not yet recruiting, Sponsor: Eli Lilly and Company
- || Aimovig (erenumab) / Amgen, Novartis
Fantastic news @Miss_CWilkinson ! #Aimovig needs to available on the #NHS @NICEComms asap! @MigraineTrust @Gus_Baldwin (Twitter) - Mar 1, 2020
- || Clinical, Journal, HEOR: How much do calcitonin gene-related peptide monoclonal antibodies improve the quality of life in migraine? A patient's perspective. (Pubmed Central) - Feb 24, 2020
Here, we highlight recent papers that uncovered novel RAMP-GPCR interactions, human RAMP-GPCR disease-causing mutations, and RAMP-related human pathologies, paving the way for a new era of RAMP-targeted drug development. CGRP-mABs have an impact on the disability, QoL, workplace productivity and global impression of improvement of migraine, which will translate into changes in the real world of migraine patients who are treated with CGRP-mABs.
- || Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion date, Trial primary completion date: A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache (clinicaltrials.gov) - Feb 23, 2020
P4, N=687, Recruiting, Sponsor: Amgen
CGRP-mABs have an impact on the disability, QoL, workplace productivity and global impression of improvement of migraine, which will translate into changes in the real world of migraine patients who are treated with CGRP-mABs. Trial completion date: May 2022 --> Dec 2022 | Trial primary completion date: Nov 2021 --> Jun 2022
- | Aimovig (erenumab) / Amgen, Novartis
How can I buy Aimovig privately in UK? (Twitter) - Feb 19, 2020
- |||| Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment open, Head-to-Head: HER-MES: Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine (clinicaltrials.gov) - Feb 17, 2020
P4, N=770, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: May 2022 --> Dec 2022 | Trial primary completion date: Nov 2021 --> Jun 2022 Active, not recruiting --> Recruiting
- | Aimovig (erenumab) / Amgen, Novartis
Clinical, Review, Journal: Nonclinical safety evaluation of erenumab, a CGRP receptor inhibitor for the prevention of migraine. (Pubmed Central) - Feb 16, 2020
The maternal and developmental no-observed-effect level (NOEL) was the highest dose tested (50 mg/kg SC Q2W). These nonclinical data in total indicate no safety signal of concern to date and provide adequate margins of exposure between the observed safe doses in animals and clinical dose levels.
- | Aimovig (erenumab) / Amgen, Novartis
Journal, HEOR: Cost-effectiveness of noninvasive vagus nerve stimulation for acute treatment of episodic migraine and role in treatment sequence strategies. (Pubmed Central) - Feb 14, 2020
We conducted a cost-effectiveness analyses for 2 hypothetical scenarios: a primary model for treatment options gammaCore plus standard of care compared to standard of care alone for acute treatment of migraine; and a secondary model for treatment sequence strategies where acute treatment with gammaCore or standard of care each prior to erenumab prevention compared to initiating erenumab prevention with no prerequisite...This was driven by efficacy, improvement in quality of life, and reduction in costs of care associated with successful treatment of migraine attacks. These findings provide new economic evidence to support value forcoverage for gammaCore.
- | Aimovig (erenumab) / Amgen, Novartis
Review, Journal: The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal. (Pubmed Central) - Feb 14, 2020
The available data suggest that erenumab 140 mg monthly might be preferred over the 70 mg monthly dose in patients with EM or CM and prior preventive treatment failures. Further data are needed to assess the long-term efficacy in clinical practice of the two doses of erenumab, while their safety profile is comparable.
- ||||| Aimovig (erenumab-aooe) / Amgen, Novartis
Biomarker, New P4 trial: INTERROGATE: Biomarker and Genetic Predictors of Erenumab Treatment Response (clinicaltrials.gov) - Feb 11, 2020
P4, N=2000, Not yet recruiting, Sponsor: Amgen
- || Aimovig (erenumab) / Amgen, Novartis
After rejection, NICE agrees to look again at migraine drug Aimovig https://t.co/CezawdulaR via @pharmaphorum (Twitter) - Feb 10, 2020
- ||| Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion: Efficacy and Tolerability of Erenumab in the Prophylactic Treatment of Persistent Post-Traumatic Headache (clinicaltrials.gov) - Feb 9, 2020
P2, N=100, Completed, Sponsor: Danish Headache Center
Further data are needed to assess the long-term efficacy in clinical practice of the two doses of erenumab, while their safety profile is comparable. Recruiting --> Completed
- || Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal: Longitudinal assessment of utilities in patients with migraine: an analysis of erenumab randomized controlled trials. (Pubmed Central) - Feb 7, 2020
P2, P3
Mapped utility values for patients treated with erenumab were generally higher than those for individuals treated with placebo with equivalent number of MMDs. Linking patient utility values to MMDs allows utility estimates for different levels of MMD to be predicted, for use in economic evaluations of preventive therapies.
- ||| There are four approved therapies for the treatment of #chronicmigraine currently: Botox, CGRP agents Aimovig (@Novartis @Amgen), Ajovy (@Teva) and Emgality (Eli Lilly), in addition to acute oral therapeutics, such as triptans. (Twitter) - Feb 6, 2020
- | Emgality (galcanezumab) / Eli Lilly, Aimovig (erenumab) / Amgen, Novartis
Aimovig is life-changing! Unfortunately, it killed my intestines. Had to stop taking it. Trying Emgality now. (Twitter) - Feb 5, 2020
- ||| Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment closed, Head-to-Head: HER-MES: Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine (clinicaltrials.gov) - Feb 5, 2020
P4, N=824, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Linking patient utility values to MMDs allows utility estimates for different levels of MMD to be predicted, for use in economic evaluations of preventive therapies. Recruiting --> Active, not recruiting
- ||||| Aimovig (erenumab-aooe) / Amgen, Novartis
New P4 trial: EMBRACE: Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine (clinicaltrials.gov) - Feb 4, 2020
P4, N=576, Not yet recruiting, Sponsor: Amgen
- | Aimovig (erenumab) / Amgen, Novartis
Hope you are feeling better @PutAimovigOnNHS .😊 (Twitter) - Feb 2, 2020
- || Aimovig (erenumab) / Amgen, Novartis
@Amgen @Novartis Is it OK to use Aimovig if someone is allergic to Aimovig? (Twitter) - Jan 31, 2020
- || Ubrelvy (ubrogepant) / AbbVie
Trial completion: Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine (clinicaltrials.gov) - Jan 30, 2020
P1b, N=40, Completed, Sponsor: Allergan
Recruiting --> Active, not recruiting Recruiting --> Completed
- |||| Aimovig (erenumab-aooe) / Amgen, Novartis
New P4 trial: Erenumab for Idiosyncratic Facial Pain (clinicaltrials.gov) - Jan 30, 2020
P4, N=66, Not yet recruiting, Sponsor: Duke University
- |||| Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion date, Trial primary completion date: OASIS (EM): Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine (clinicaltrials.gov) - Jan 30, 2020
P3, N=456, Recruiting, Sponsor: Amgen
Recruiting --> Completed Trial completion date: Dec 2023 --> May 2025 | Trial primary completion date: Dec 2022 --> May 2024
- || Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion date, Trial primary completion date: AMG 334 20160172 Pediatric Migraine PK Study. (clinicaltrials.gov) - Jan 30, 2020
P1, N=60, Recruiting, Sponsor: Amgen
Trial completion date: Dec 2023 --> May 2025 | Trial primary completion date: Dec 2022 --> May 2024 Trial completion date: Jun 2021 --> Oct 2021 | Trial primary completion date: Jun 2020 --> Jul 2021
- ||| TEV-48125 / Teva, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
HEOR: Are you listening @NICEComms ? #chronicmigraine #fremanezumab #erenumab #costeffective @NatMigraineCtr @KatyMunro1 @annamaclean8 @migrainewales @MigraineTrust (Twitter) - Jan 24, 2020
- Aimovig (erenumab) / Amgen, Novartis
Safety and tolerability of erenumab in older migraine patients: A subgroup analysis of randomised trials () - Jan 21, 2020 - Abstract #AAN2020AAN_2945;
P2, P3
Erenumab is safe and well-tolerated in older patients with CM and EM. Safety and tolerability in the erenumab treatment groups is comparable across different age groups.